Global Genotyping Market By Product (Instruments, Reagents & Kits, and Software & Services), By Technology (PCR, Capillary Electrophoresis, Microarray, Sequencing, Mass Spectrometry, and Other Technologies), By Application (Plastics, Inks, and Coatings), By Application (Pharmacogenomics, Diagnostics And Personalized Medicine, Agricultural Biotechnology, Animal Genetics, and Other Applications), By End-Use (Pharmaceutical And Biopharmaceutical Companies, Diagnostics And Research Laboratories, Academic Institutes, and Other End-Uses), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032

Genotyping Market Overview:

In 2021, the global genotyping market was valued at USD 12,650 million. The market is estimated to grow at a compound annual growth rate (CAGR) of 15.42% between 2022-2032.

This growth can be attributed primarily to technological advances, increasing prevalence of cancer and genetic disorders, as well as increased R&D funding for precision medicine research.

A positive impact was also seen by the COVID-19 Pandemic on the genotyping market. The increased demand for COVID-19-genotyping kits resulted in a higher level of sales. SNP genotyping is used to identify genetic variants of the Covid-19 virus.

Global Genotyping Market Analysis:

Product Analysis:

The largest share of 2021 was held by the reagents, kits, and chemicals segment. This is due in part to increasing demand for genetic tests, increasing investments in R&D, and increased genotyping test volumes.

Due to the increasing adoption of software-based services by academic institutions and research labs, the software & Services segment will also grow. Bioinformatics helps to improve the efficiency of sequencing methods and avoids mistakes that are common in traditional sequencing methods.

These services can be used in agrigenomics as well as for diagnosing and treating diseases of animals and microbes. The market is expected to grow due to all of the above factors.

Application Analysis:

Pharmacogenomics will be the fastest-growing technology in the forecast period. Genotyping is used to identify the most suitable patients for a specific drug by using their genetic makeup.

It helps to identify subsets of people that are responsive and non-responsive. It also helps to reduce trial attrition. In addition, key players are involved in providing solutions for pharmacogenomics.

Thermo Fisher Scientific offers RT-PCR solutions for pharmacogenomic testing. This includes QuantStudio instruments and TaqMan assays. It also includes a PharmacoScan solution, as well as a PharmacoScan Kit.
Due to the increasing adoption of genetic products for research and the growing demand for diagnosis and treatment of genetic diseases, the largest share of the genotyping market is in diagnostics and personalized medicines. The market will grow through strategic collaborations between players.

Technology Analysis:

Major factors driving the market growth are the growing demand for advanced diagnostic methods, increasing numbers of CROs and forensic & laboratory laboratories, as well as rising prevalence of chronic diseases and genetic disorders.

The increased specificity of sequencing and its ability to detect the low expression and differentially expressed genes is expected to drive the industry forward. Genotyping through sequencing can also be used to perform comparative analyses across samples without the use of a reference gene.

End Use Analysis:

The fastest-growing segment in diagnostics and laboratory services is the research laboratories and research labs. This is due to the rising adoption of genotyping tools for research and the increasing demand for diagnosing genetic diseases and cancer.

Market growth is expected to be driven by the rising prevalence of cancer. Market growth will be driven by the increasing demand for pharmacogenomics in drug development and FDA recommendations to include genotyping and pharmacogenomics studies in drug discovery.

To develop new drugs, pharmacogenomics is actively used by companies. Pfizer has launched a genotyping-based trial to evaluate the effectiveness of Talazoparib for patients with metastatic BRCA mutant-resistant breast cancer.

The increasing number of clinical studies based on Pharmacogenomics will drive segment growth.

Key Market Segments:

By Product

• Instruments
• Reagents & Kits
• Software & Services

By Technology

• PCR
• Capillary Electrophoresis
• Microarray
• Sequencing
• Mass Spectrometry
• Other Technologies

By Application

• Pharmacogenomics
• Diagnostics And Personalized Medicine
• Agricultural Biotechnology
• Animal Genetics
• Other Applications

By End-Use

• Pharmaceutical And Biopharmaceutical Companies
• Diagnostics And Research Laboratories
• Academic Institutes
• Other End-Uses

Market Dynamics:

A rise in government funding is expected to propel the genotyping market, especially for genome research by both government bodies and pharma/biotechnology companies to speed up research.

Worldwide, the number of chronic diseases such as cancer and other genetic disorders is on the rise. This is expected to increase the demand for genotypic diagnostic testing.

About 20% of cancer deaths worldwide can be attributed to viruses that cause cancer, such as the Human Papilloma Virus(HPV) or Hepatitis B Virus/Hepatitis Virus.

Based on population growth, and aging, it is predicted that the number of cancer cases will rise by approximately 70% over the next 20 decades. The market’s main driver is likely to be the rising incidence of cancer.

However, the lack of skilled technicians in developing countries could slow down market growth. Because genotyping data analysis requires high levels of technical expertise, and management, and also requires high levels of technical knowledge. At the moment, there are very few experts and professionals in developing nations.

Local players can expect to take strategic steps to increase market growth. For example, VG Acquisition Corp. merged in February 2021 with 23andMe (a U.S.-based research and genetics company) that specializes in direct-to-consumer genotyping solutions. This merger would allow them to raise capital for their genetic consumer business.

Regional Analysis:

North America had the largest market share of 2021. This is due to the growing adoption of advanced products, major pharmaceutical & biologic companies, proactive government initiatives, and advancements in healthcare infrastructure.

High market share can also be attributed to the presence of large players in this region. Europe is expected to experience a rapid CAGR over the forecast period.

Many factors are responsible for the enormous untapped potential of Europe, such as technological advancements in the region and the expanding pharma/biopharma sector.

The Asia Pacific is expected to have the best opportunities. Additionally, there are more clinical trials being performed in this region.

Кеу Regions and Countries covered іn thе rероrt:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Spain
  • Rest of Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Rest of Asia-Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• MEA
  • GCC
  • South Africa
  • Israel
  • Rest of MEA

Key Companies & Market share Analysis:

To maintain market share, key players have adopted strategies like partnerships and product launches. Illumina and Roche, for instance, collaborated in January 2020 to increase access to oncology genomic tests. Illumina also invested in seven companies in genomics across different countries under its Illumina Accelerator Program in September 2021.

Key Market Players:

• Illumina Inc.
• Thermo Fisher Scientific Inc.
• Qiagen Inc.
• F. Hoffmann-La Roche Ltd.
• Fluidigm Corporation
• Danaher Corporation
• Agilent Technologies
• Eurofins Scientific Inc.
• Other Key Players

For the Genotyping Market research study, the following years have been considered to estimate the market size: